- Home
- /
- Semaglutide 10mg
Semaglutide 10mg
Certificate of Analysis
HPLC + Mass Spectrometry included with order
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native human GLP-1. It features a C-18 fatty acid chain modification that enables binding to albumin, extending its half-life to approximately 7 days in preclinical models.
Semaglutide is one of the most extensively studied peptides in modern pharmaceutical research, with multiple approved formulations (Ozempic, Wegovy, Rybelsus) across metabolic and cardiovascular indications. Published research spans glycaemic control, appetite regulation, cardiovascular outcomes, and body composition.
Kyrolab supplies semaglutide in research-grade vials across multiple dosages for diverse protocol requirements.
Independently Verified Purity: 99.556% / 99.581%
Tested by Janoshik Analytical (Prague) — Task #83224, 15 October 2025.
2 separate vials tested for batch consistency:
Vial 1: 11.12mg, 99.556% purity
Vial 2: 11.47mg, 99.581% purity
Batch: 2025C52-10 | Sky blue cap identifier.
Verification: janoshik.com/verify — Key:
TPS25DJM8HXY
Specifications
| Molecular Weight | 4113.58 g/mol |
| CAS | 910463-68-2 |
| Receptor | GLP-1R agonist |
| Half-life | ~7 days (preclinical) |
| Dose | 10mg per vial |
| Appearance | White lyophilised powder |
| Storage | 2-8°C, protect from light |
This product is sold strictly for in-vitro research and laboratory purposes. Not for human or animal consumption. Not evaluated by the MHRA or FDA. Must be 18+ to purchase. By purchasing, you agree to our Research Disclaimer and Terms of Service.
| Catalogue Number | KYR-SEMAGLUTIDE10MG |
| Compound Name | Semaglutide 10mg |